Departure. Clinical Miss. Billion: Should You Bet on Pfizer?
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
We examine altcoins with strong funding, evaluating how capital enables development pace, partnerships, and long-term roadmap execution.
17,339 articlesPfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
The GAO is signaling tougher oversight for AI vendors serving the federal government, with new standards on data disc...
Autonomous AI agents paying for goods and services could redefine digital commerce. This article examines how Ripple ...
Public safety officers can tap 457(b) funds penalty-free after leaving service, potentially enabling early retirement...
As Nasdaq income options proliferate, investors weigh tax treatment and true take-home yields. A clear, current compa...
Microsoft has pulled back from recent highs, stirring questions about its value versus the S&P 500. This guide explai...
Warren Buffett publicly stated he initiated Berkshire Hathaway’s larger stake in Alphabet, signaling a top-down push ...
As BTC consolidates in 2026, Coinbase, BlackRock and Strategy emerge as the top on-chain holders. This report breaks ...
As the Q4 2025 earnings season unfolds, savvy investors turn to transcripts to separate sound bites from real signal....
A new study from Engel & Volkers tracks how the next generation of high-earning buyers is overturning luxury home tre...
Lucid delivered higher volumes and nudged toward improving efficiency, signaling a potential turn in its long EV jour...
Understanding runway growth (rway) earnings helps you assess whether a young company can sustain momentum. Learn key ...